GlassScriptPhysician profile
Krishna K Raman
NPI 1922048958
$5,322.54
in general payments reported to CMS, 2019-2025
25 companies · $1,225 in 2025
The $1,225 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $430 · 2020: $267 · 2021: $389 · 2022: $589 · 2023: $1,161 · 2024: $1,261 · 2025: $1,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,644 · Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,644.20 |
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,401.28 | 2021-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $712.63 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $705.67 | 2021-2025 | |
| Amgen INC. | $279.81 | 2019-2025 | Tavneos, Parsabiv |
| Vifor Pharma, INC. | $257.43 | 2021-2025 | Veltassa |
| Glaxosmithkline, LLC. | $238.23 | 2022-2024 | Jesduvroq, Benlysta |
| Calliditas Therapeutics US INC. | $232.50 | 2022-2025 | Tarpeyo |
| Medtronic, INC. | $211.85 | 2023 | Ellipsys Vascular Access System |
| Mallinckrodt Hospital Products INC. | $179.04 | 2022-2025 | Acthar, Terlivaz |
| Lilly USA, LLC | $178.89 | 2024-2025 | Jardiance |
| Akebia Therapeutics INC | $155.09 | 2019-2021 | |
| Horizon Therapeutics Plc | $151.04 | 2020-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $132.85 | 2024-2025 | |
| Ardelyx, INC. | $107.19 | 2025 | Ibsrela |
| Opko Pharmaceuticals, LLC | $103.79 | 2023-2025 | Rayaldee |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $49.26 | 2023-2024 | Lupkynis |
| Travere Therapeutics, INC. | $46.98 | 2023-2024 | |
| Ani Pharmaceuticals, INC. | $36.83 | 2025 | Purified Cortrophin Gel |
| Ultragenyx Pharmaceutical INC. | $27.53 | 2023 | Crysvita |
| Recor Medical INC | $27.22 | 2025 | Paradise Ultrasound Renal Denervation System |
| Takeda Pharmaceuticals U.S.A., INC. | $24.90 | 2025 | Gattex |
| Fresenius USA Marketing, INC. | $17.73 | 2019 | |
| Shire North American Group INC | $17.42 | 2019 | |
| Novo Nordisk INC | $14.27 | 2024 | Rybelsus, Ozempic |
| Genzyme Corporation | $13.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishna Raman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.